

UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

07/387,003

GELFAND 07/28/89

KEVIN R. KASTER CETUS CORPORATION 1400 53RD ST. EMERYVILLE, CA 94508

188

05/03/91

Ο π	his a	pplication has been examined Responsive to communication filed on	This action is made final.	
A shortened statutory period for response to this action is set to expire month(s), days from the date of this letter. Failure to respond within the period for response will cause the application to become abandoned. 35 U.S.C. 133				
Part I	Part I THE FOLLOWING ATTACHMENT(S) ARE PART OF THIS ACTION:			
1. 3. 5.	=	Notice of References Cited by Examiner, PTO-892. Notice of Art Cited by Applicant, PTO-1449. Information on How to Effect Drawing Changes, PTO-1474. 2. Notice re Patent Drawing, PTO-948. Notice of Informal Patent Application, Form PTO-152.		
Part I				
1.	A	Claims 35-4/453-62	are pending in the application.	
		Of the above, claims are w	rithdrawn from consideration.	
2.		Ctalms	have been cancelled.	
3.		Claims		
4.	A	Claims 35-41 453-62	are rejected.	
5.		Claims	are objected to.	
6.		Ctaims are subject to restriction	n or election requirement.	
7.		This application has been filed with informal drawings under 37 C.F.R. 1.85 which are acceptable for examination purposes.		
8.		Formal drawings are required in response to this Office action.		
9.		The corrected or substitute drawings have been received on Under 37 C.F.R. 1.84 these drawings acceptable. on acceptable (see explanation or Notice re Patent Drawing, PTO-948).		
10.	Ö	the proposed additional or substitute sheet(s) of drawings, filed on has (have) been approved by the examiner disapproved by the examiner (see explanation).		
11.		he proposed drawing correction, filed on, has been 🔲 approved. 🗀 disapproved (see explanation).		
12.		Acknowledgment is made of the claim for priority under U.S.C. 119. The certified copy has 🔲 been received 🔲 not been received		
		been filed in parent application, serial no; filed on		
13.		Since this application appears to be in condition for allowance except for formal matters, prosecution as to accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213.	the merits is closed in	
	_			

EXAMINER'S ACTION

Serial No. 07/387,003 Art Unit 188

5

10

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claims 1, 35-39 and 53-59 are rejected under 35 U.S.C. § 102(a) as being anticipated by the MBR product information sheet as set forth in the previous office action of 9/4/90.

Applicants have filed a 37 CFR §1.131 Declaration containing a copy of a description of a <u>Taq</u> polymerase purification protocol and a stabilized enzyme composition supplied to MBR prior to 5/1/87. However, the declaration is defective in being signed by only one co-inventor. One of joint inventors may make the declaration only when the claim rejected is the invention of only this inventor or it is not possible to produce the other joint inventors(MPEP 715.04).

The declaration is further inadequate in that the

description relied on as evidence fails to set forth that the

nonionic polymeric detergent stabilizes the thermostable nucleic

acid polymerase enzyme during storage. In the description of

purifying the thermostable polymerase, the diluent and nonionic

detergent therein are being used in carrying out a process of

purification. The formation of a composition is only incidental

to carrying out the process, and the composition is not being

prepared with the objective of producing a composition that is

stable during storage. While the last page of the description,

discloses a 2X storage buffer containing a nonionic detergent as

asserted by applicants, there is no recognition in the

Serial No. 07/387,003 Art Unit 188

5

10

15

25

description that the nonionic detergent is functioning to stabilize a thermostable polymerase during storage. The nonionic detergent could have been used for another function such as to prevent aggregation as disclosed by Goff et al(col 20, lines 24-Storage stability could have been believed to result from the glycerol. DTT and other components present in the 2X storage buffer. The 2X storage buffer contains components and proportions not required by the present claims and not contained by the MBR storage buffer. For example, the 2X buffer contains NP40 and Tween 20 whereas the MBR buffer contains only Tween 20, and the proportions of all components of the MBR buffer are different from the proportions of the components of the 2X buffer. Thus, the MBR buffer is a species different from the 2X buffer and both are within the scope of the present claims. chemical cases, where generic claims have been rejected on a reference which discloses a species not antedated by the affidavit or declaration, the rejection is not withdrawn(MPEP 715.03).

Claims 40, 41 and 60-62 are rejected under 35 U.S.C. § 103

20 as being unpatentable over the product information sheet of MBR for reasons set forth in the previous office action.

As noted above, the 37 CFR §1.131 Declaration fails to obviate the MBR reference.

Claims 1, 35-41, 53-59 and 62 are rejected under 35 U.S.C. § 103 as being unpatentable over Kaledin et al(1980) in view of

Serial No. 07/387,003 Art Unit 188

5

10

15

20

25

-4-

Goff et al and, if necessary, in further view of Feller et al or Spiegelman for reasons set forth in the previous office action.

Applicant's arguments filed 2/11/91 have been fully considered but they are not deemed to be persuasive.

Applicants urge that Kaledin et al believed that any problem of thermostable polymerase stability had been solved since the introduction of gelatin was disclosed to stabilize enzymatic activity, and there is no motivation to change the formulation of the reference to overcome a problem of stability. However, when Goff et al and, if needed, Feller et al or Spiegelman are considered, it would have been apparent that in addition to gelatin a nonionic detergent would have also functioned to stabilize the polymerase. To use an alternative stabilizing agent known for polymerase stabilization would have been a matter of obvious choice depending on individual preference and convenience. Furthermore, to select a preferred stabilizing agent from these known would have required only limited routine experimentation and have been within the skill of the art. In any event, Goff et al disclose(col 20, line 25) that in addition to preventing loss of activity the nonionic detergent prevents This would have been an additional result obtained aggregation. from using a nonionic detergent that would have been a motivation to select the detergent rather than gelatin for stabilizing. Furthermore, the nonionic detergent of Goff et al is present in a buffer used during lysis(col 20, line 21) and other purification

steps, and for storage of the enzyme. This use of the detergent in multiple stages would have been motivation for its use rather than gelatin which is used only in one stage.

Applicants urge that Goff et al recover reverse 5 transcriptase enzyme and does not suggest stability problems associated with thermostable polymerase. However, reverse transcriptase is a DNA polymerase enzyme(Feller et al(col 1, lines 65-68)), and Goff et al clearly disclose using a nonionic detergent to maintain activity. It would have been obvious that 10 the nonionic detergent would have maintained the activity of DNA polymerase in the absence of something to lead one to believe the contrary. There is seen nothing to lead one to believe that a polymerase being thermostable changes its characteristics so as to make unexpected a nonionic detergent functioning to stabilize 15 the enzyme as suggested by Goff et al and, if needed, Feller et al or Spiegelman. Being thermostable merely means that the DNA polymerase is stable at a higher temperature. Such a polymerase would otherwise be expected to have the characteristics and function of other DNA polymerase. It is clearly apparent from 20 Kaledin et al(1980), as well as Kaledin et al(1981), that thermostable DNA polymerase loses activity like other DNA polymerase as disclosed by other references without a stabilizing agent being present. The type of comments set forth above in response to applicants' arguments concerning Goff et al also 25 apply to Feller et al and Spiegelman.

5

10

25

Claims 60 and 61 are rejected under 35 U.S.C. § 103 as being unpatentable over the references as applied to claims 1, 35-41, 53-59 and 62 above, and further in view of Kaledin et al(1981) or Ruttimann et al(1985) for reasons set forth in the previous office action.

The type of comments set forth above in response to arguments also apply to this rejection.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 C.F.R. § 1.136(a). The practice of automatically extending the shortened statutory period an additional month upon the filing of a timely first response to a final rejection has been discontinued by the Office. See 1021 TMOG 35.

A SHORTENED STATUTORY PERIOD FOR RESPONSE TO THIS FINAL

ACTION IS SET TO EXPIRE THREE MONTHS FROM THE DATE OF THIS

ACTION. IN THE EVENT A FIRST RESPONSE IS FILED WITHIN TWO MONTHS

OF THE MAILING DATE OF THIS FINAL ACTION AND THE ADVISORY ACTION
IS NOT MAILED UNTIL AFTER THE END OF THE THREE-MONTH SHORTENED

STATUTORY PERIOD, THEN THE SHORTENED STATUTORY PERIOD WILL EXPIRE

ON THE DATE THE ADVISORY ACTION IS MAILED, AND ANY EXTENSION FEE
PURSUANT TO 37 C.F.R. § 1.136(a) WILL BE CALCULATED FROM THE

MAILING DATE OF THE ADVISORY ACTION. IN NO EVENT WILL THE

STATUTORY PERIOD FOR RESPONSE EXPIRE LATER THAN SIX MONTHS FROM
THE DATE OF THIS FINAL ACTION.

Any inquiry concerning this communication should be directed to Examiner Naff at telephone number (703) 308-0520.

DAVID M. NAFF
PRIMARY EXAMINER
ART UNIT 188